UnknownNot Applicable

Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum

Turkey (Türkiye)90 participantsStarted 2021-11-14

Plain-language summary

We planed to evaluate soluble the triggering receptors expressed on myeloid cell-1 (s TREM-1) levels in serum of pregnant women diagnosed with placenta accreta spectrum and compare it with healthy pregnant women's s TREM-1 serum levels.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: placenta accreta spectrum diagnosis. 3rd trimester pregnancy, not having any additional disease, not in labor, not having multiple pregnancy. Exclusion Criteria:having multiple pregnancy, having any additional disease (preeclampsia, gestational diabetes mellitus, etc) , having an infection, being in labor. \-

What they're measuring

sTREM-1 levels

Timeframe: after 12 hours fasting

Trial details

NCT IDNCT05376410

SponsorNecmettin Erbakan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-01

Contact for this trial

hasan energin, dr.

00905530619041 hasanenergin@gmail.com

View on ClinicalTrials.gov More Placenta Accreta, Third Trimester trials